• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reconsidering the Meaning of Curing Primary Breast Cancer as a Systemic Disease.

作者信息

Kim Ryungsa, Kin Takanori

机构信息

Department of Breast Surgery, Hiroshima Mark Clinic, Hiroshima, Japan.

Department of Breast Surgery, Hiroshima City Hospital, Hiroshima, Japan.

出版信息

Front Oncol. 2021 Mar 18;11:639420. doi: 10.3389/fonc.2021.639420. eCollection 2021.

DOI:10.3389/fonc.2021.639420
PMID:33816282
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8012902/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2091/8012902/649ef873aaa8/fonc-11-639420-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2091/8012902/649ef873aaa8/fonc-11-639420-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2091/8012902/649ef873aaa8/fonc-11-639420-g0001.jpg

相似文献

1
Reconsidering the Meaning of Curing Primary Breast Cancer as a Systemic Disease.重新审视将原发性乳腺癌作为一种全身性疾病进行治愈的意义。
Front Oncol. 2021 Mar 18;11:639420. doi: 10.3389/fonc.2021.639420. eCollection 2021.
2
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
3
Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.基于残余肿瘤负担、新辅助治疗反应指数和 Neo-Bioscore 评估的 HER2 阳性乳腺癌新辅助治疗后残余疾病的预后价值。
Clin Cancer Res. 2019 Aug 15;25(16):4985-4992. doi: 10.1158/1078-0432.CCR-19-0560. Epub 2019 May 10.
4
Biomarkers of residual disease after neoadjuvant therapy for breast cancer.乳腺癌新辅助治疗后残留疾病的生物标志物。
Nat Rev Clin Oncol. 2016 Aug;13(8):487-503. doi: 10.1038/nrclinonc.2016.1. Epub 2016 Feb 9.
5
Primary systemic therapy of breast cancer.乳腺癌的原发性全身治疗
Oncologist. 2006 Jun;11(6):574-89. doi: 10.1634/theoncologist.11-6-574.
6
Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.可手术乳腺癌患者新辅助化疗后的保乳手术
Ann Ital Chir. 2018;89:290.
7
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.乳腺癌新辅助与辅助全身治疗的荟萃分析
J Natl Cancer Inst. 2005 Feb 2;97(3):188-94. doi: 10.1093/jnci/dji021.
8
Comparing Accuracy of Mammography and Magnetic Resonance Imaging for Residual Calcified Lesions in Breast Cancer Patients Undergoing Neoadjuvant Systemic Therapy.比较新辅助全身治疗后乳腺癌患者残留钙化病变的乳腺 X 线摄影术和磁共振成像的准确性。
Clin Breast Cancer. 2018 Oct;18(5):e1087-e1091. doi: 10.1016/j.clbc.2018.03.011. Epub 2018 Mar 15.
9
Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.紫杉烷类药物在乳腺癌辅助治疗和新辅助治疗中的新作用：潜力与问题
Surg Clin North Am. 2003 Aug;83(4):943-71. doi: 10.1016/S0039-6109(03)00071-9.
10
[Neoadjuvant systemic therapy in breast cancer].[乳腺癌的新辅助全身治疗]
Orv Hetil. 2009 Jan 11;150(2):65-71. doi: 10.1556/OH.2009.28536.

引用本文的文献

1
Higher peripheral blood mitochondrial DNA copy number and relative telomere length in under 48 years Indonesian breast cancer patients.48 岁以下印度尼西亚乳腺癌患者外周血线粒体 DNA 拷贝数和相对端粒长度较高。
BMC Res Notes. 2024 Apr 28;17(1):120. doi: 10.1186/s13104-024-06783-y.

本文引用的文献

1
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.早期三阴性乳腺癌患者新辅助阿替利珠单抗联合序贯纳武利尤单抗和基于蒽环类的化疗与安慰剂和化疗相比：一项随机、双盲、III 期试验（IMpassion031）。
Lancet. 2020 Oct 10;396(10257):1090-1100. doi: 10.1016/S0140-6736(20)31953-X. Epub 2020 Sep 20.
2
Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy.循环肿瘤DNA可预测接受新辅助化疗的早期乳腺癌患者的反应和预后。
JCO Precis Oncol. 2020 Mar 27;4. doi: 10.1200/PO.19.00292. eCollection 2020.
3
Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer.将免疫疗法纳入早期乳腺癌（新）辅助治疗。
Curr Opin Oncol. 2020 Nov;32(6):575-584. doi: 10.1097/CCO.0000000000000675.
4
Clinical Impact of Breast Cancer Stem Cells in Metastatic Breast Cancer Patients.乳腺癌干细胞在转移性乳腺癌患者中的临床影响
J Oncol. 2020 Jun 27;2020:2561726. doi: 10.1155/2020/2561726. eCollection 2020.
5
Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study.探讨生活方式对乳腺癌风险、诊断时年龄和生存的影响：EBBA-Life 研究。
Breast Cancer Res Treat. 2020 Jul;182(1):215-227. doi: 10.1007/s10549-020-05679-2. Epub 2020 May 20.
6
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.乳腺癌：一种需要亚型特异性治疗的分子异质性疾病。
Med Sci (Basel). 2020 Mar 23;8(1):18. doi: 10.3390/medsci8010018.
7
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.帕博利珠单抗联合新辅助化疗对早期乳腺癌患者病理完全缓解的影响：正在进行的 2 期适应性随机 I-SPY2 试验分析。
JAMA Oncol. 2020 May 1;6(5):676-684. doi: 10.1001/jamaoncol.2019.6650.
8
Stem Cells and Cellular Origins of Breast Cancer: Updates in the Rationale, Controversies, and Therapeutic Implications.干细胞与乳腺癌的细胞起源：理论依据、争议及治疗意义的最新进展
Front Oncol. 2019 Aug 28;9:820. doi: 10.3389/fonc.2019.00820. eCollection 2019.
9
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.个体化循环肿瘤 DNA 分析检测乳腺癌新辅助治疗后的残留病灶。
Sci Transl Med. 2019 Aug 7;11(504). doi: 10.1126/scitranslmed.aax7392.
10
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.一项随机 II 期研究，旨在探讨在早期三阴性乳腺癌中，在蒽环类药物紫杉烷为基础的新辅助治疗中加入度伐利尤单抗的效果：GeparNuevo 研究的临床结果和生物标志物分析。
Ann Oncol. 2019 Aug 1;30(8):1279-1288. doi: 10.1093/annonc/mdz158.